Grifols (GRFS) Stock Forecast & Price Target

$7.74

-0.04 (-0.51%)

(As of 07/26/2024 ET)

Grifols - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce
Based on 3 Analyst Ratings

Based on 3 Wall Street analysts who have issued ratings for Grifols in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 3 analysts, 1 has given a sell rating, and 2 have given a hold rating for GRFS.

Consensus Price Target

$10.50
35.66% Upside

High Forecast	$10.50
Average Forecast	$10.50
Low Forecast	$10.50

According to the 3 analysts' twelve-month price targets for Grifols, the average price target is $10.50. The highest price target for GRFS is $10.50, while the lowest price target for GRFS is $10.50. The average price target represents a forecasted upside of 35.66% from the current price of $7.74.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Reduce	Reduce	Reduce	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	3 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$10.50	$10.50	$10.50	N/A
Forecasted Upside	35.66% Upside	6.82% Upside	6.82% Upside	N/A

Get Grifols Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

Ad Porter & Company

Obama wins Presidential debate

When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.”

Please, watch this now before it’s too late.

GRFS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GRFS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Grifols Stock vs. The Competition

Type	Grifols	Medical Companies	S&P 500
Consensus Rating Score	1.67	2.72	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	35.66% Upside	3,123.46% Upside	9.10% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
3/12/2024	Deutsche Bank Aktiengesellschaft 2 of 5 stars	Downgrade	Hold ➝ Sell
12/5/2023	JPMorgan Chase & Co. 3 of 5 stars	Boost Target	Neutral ➝ Neutral	$10.00 ➝ $10.50	+6.82%
8/29/2023	Morgan Stanley 3 of 5 stars	Downgrade	Overweight ➝ Equal Weight
2/16/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight
2/6/2023	AlphaValue Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy
1/18/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
11/25/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:52 AM ET.

GRFS Forecast - Frequently Asked Questions

What is Grifols' forecast for 2024?: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Grifols is $10.50, with a high forecast of $10.50 and a low forecast of $10.50.
Should I buy or sell Grifols stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last twelve months. There is currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" GRFS shares.
Does Grifols's stock price have much upside?: According to analysts, Grifols's stock has a predicted upside of 6.82% based on their 12-month stock forecasts.
Do Wall Street analysts like Grifols more than its competitors?: Analysts like Grifols less than other "medical" companies. The consensus rating for Grifols is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GRFS compares to other companies.